logo
Texas Stock Exchange hires top ETF executives from Cboe, Nasdaq

Texas Stock Exchange hires top ETF executives from Cboe, Nasdaq

Yahoo14-03-2025
By Suzanne McGee
(Reuters) - The Texas Stock Exchange (TSXE), still months away from winning regulatory approval to begin operations, said it hired senior exchange-traded funds executives from Cboe Global Markets and Nasdaq to win a share of trading in the $11 trillion U.S. ETF market.
It announced on Thursday that Robert Marrocco, formerly global head of ETP, or exchange-traded products, listings at Cboe Global Markets, will take on the same role at TXSE and Alison Hennessy, the former head of ETP listings at Nasdaq, will become managing director of exchange traded products.
The hirings signal the Texas exchange views the ETF arena as key to its future growth, analysts said.
"The fact that they are poaching top talent from two of the three biggest exchanges sends a clear signal that they are to be taken seriously" as a future competitor in the ETF sector, said Bryan Armour, ETF strategist at Morningstar.
The TXSE, which has disclosed that it has raised about $161 million in capital from some four dozen investors that include financial giants BlackRock, Citadel Securities and Charles Schwab, filed paperwork in late January seeking regulatory approval to operate a national securities exchange. It hopes to win approval later this year and to begin listing and trading in early 2026.
The hirings not only bolster the TXSE's roster but also may end up creating challenges for the incumbent exchanges, said one market structure analyst, who asked not to be named because his firm does not permit him to comment publicly. In a rapidly growing area such as ETFs, losing top executives to a potential rival is "less than ideal," the analyst said.
"Together, these leaders managed more than 40% of all (exchange-traded products) in the United States," the Texas exchange said in a press release.
A spokesperson for Nasdaq declined comment on Hennessy's departure.
"We wish them well in their future endeavors," Cboe said in an statement, referring to Marrocco and two other Cboe staffers that TXSE also hired.
In its press release, TXSE said that under Marrocco's leadership since 2020, Cboe captured nearly 30% of all new ETP listings.
Marrocco did not respond to requests for comment and a TXSE spokesperson said neither he nor Hennessy were available to discuss their new roles. In a post on LinkedIn, he described TXSE as being "the next chapter of U.S. capital markets."
Marrocco's hiring "indicates that TXSE could prioritize ETP listing, which is a relatively less competitive avenue compared to individual stock listing," said Owen Lau, a senior analyst at Oppenheimer & Co.
The three exchanges that dominate the U.S. stock and ETF trading market have already responded to the TXSE's moves to establish itself as a competitive force. Last month, the New York Stock Exchange announced plans to open its own NYSE Texas division.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Algorhythm Holdings to Announce its Financial Results for the Second Quarter 2025
Algorhythm Holdings to Announce its Financial Results for the Second Quarter 2025

Yahoo

time25 minutes ago

  • Yahoo

Algorhythm Holdings to Announce its Financial Results for the Second Quarter 2025

Fort Lauderdale, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. ('Algorhythm Holdings' or the 'Company') (NASDAQ: RIME), an AI technology holding company, today announced that it will release its second quarter 2025 earnings today, Tuesday August 19, 2025 after market close. Management will host a conference call tomorrow, Wednesday, August 20, 2025, at 10:00 a.m. Eastern Time to discuss the financial results and provide a business update. Conference Call Details: Date: Wednesday, August 20, 2025Time: 10:00 a.m. EDT Dial-in number: 888-999-3182Conference ID: RIME An audio rebroadcast of the call will be available later in the day at: About Algorhythm Holdings Algorhythm Holdings, Inc. is an AI technology holding company with one primary business unit – SemiCab. SemiCab is an emerging leader in the global logistics and distribution industry. Since 2020, SemiCab has enabled major retailers, brands and transportation providers to address these common supply-chain problems globally. Its AI-enabled, cloud-based Collaborative Transportation Platform achieves the scalability required to predict and optimize millions of loads and hundreds of thousands of trucks. SemiCab uses real-time data from API-based load tendering and pre-built integrations with TMS and ELD partners to orchestrate collaboration across manufacturers, retailers, distributors, and their carriers. SemiCab uses AI/ML predictions and advanced predictive optimization models to enable fully-loaded round trips. With SemiCab's AI platform, shippers pay less and carriers make more without having to change a thing. For additional information, please go to: Investor Relations Contact: Brendan Hopkins407-645-5295investors@ Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in Algorhythm's reports to the SEC, including, without limitation Algorhythm's Annual Report on Form 10-K for the year ended December 31, 2024. You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this press release to conform our statements to actual results or changed expectations, or as a result of new information, future events or otherwise. Sign in to access your portfolio

Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution
Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution

Yahoo

time25 minutes ago

  • Yahoo

Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution

SOUTH SAN FRANCISCO, Calif., August 19, 2025--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. "We designed this panel to break the status quo in genomic profiling by offering laboratories a powerful alternative to locked, one-size-fits-all solutions," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "With our customizable content, flexible workflow, and compatibility with multiple sequencing platforms, Twist's Oncology DNA CGP Panel puts scientific control back in the hands of researchers and clinicians, particularly for those who need a more cost-effective solution compared to existing CGP products or a more efficient option than smaller panels." The Twist Oncology DNA CGP Panel was designed to serve a wide range of research groups including regional clinical labs, academic medical centers, and biopharma partners. The panel composition incorporates clinical research and includes a comprehensive and updated biomarker list covering 562 genes that incorporate all major tumor types. The panel's coverage spans genomic alterations and genomic signatures and can detect base substitutions, insertions and deletions (indels), copy number variations (CNVs), gene rearrangements as well as measure tumor mutational burden (TMB) and microsatellite instability (MSI). This is paired with Twist high quality and easy-to-use library preparation and target enrichment workflows. Twist is collaborating with several analytics companies to provide a complete solution from sequencing to analysis. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about the expected future benefits and impact of the Twist Oncology DNA CGP Panel and collaborations with analytics companies. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on Contacts For Investors: Angela BittingSVP, Corporate Affairs925-202-6211abitting@ For Media: Amanda HoulihanCommunications Manager774-265-5334ahoulihan@

ITURAN LOCATION AND CONTROL LTD Announces Dividend Distribution of $10 Million for the Second Quarter of 2025
ITURAN LOCATION AND CONTROL LTD Announces Dividend Distribution of $10 Million for the Second Quarter of 2025

Yahoo

timean hour ago

  • Yahoo

ITURAN LOCATION AND CONTROL LTD Announces Dividend Distribution of $10 Million for the Second Quarter of 2025

AZOUR, Israel, Aug. 19, 2025 /PRNewswire/ -- Ituran Location and Control Ltd. (NASDAQ: ITRN) announced that the Board of Directors approved the distribution of a cash dividend in the amount of $0.50 per share, totaling approximately US$ 10 million. The dividend will be paid to shareholders of record as of September 25, 2025. The Company will pay the dividend out on October 10, 2025, net of taxes at the rate of 25%. In its decision to approve the distribution of the cash dividend, the Board of Directors examined whether the Company meets the distribution criteria according to Israeli law. The Board of Directors concluded that the above-mentioned distribution will not undermine the Company's ability to keep performing in its current course of business or future plans, and is able to meet its undertakings when due. Retained earnings as of June 30, 2025, prior to the distribution was US$ 234.3 million and retained earnings will reach US$ 224.3 million after the distribution. The Board of Directors emphasized that as of June 30, 2025, the Company had a cash balance in hand of US$ 88.7 million (this amount is prior to the payment of a dividend of approximately US$ 10 million which was issued for the first quarter 2025 and was paid out in July 2025). The Company had no outstanding credit from banking institutions. As of June 30, 2025, the Company's current assets (excluding cash and cash equivalents) were in the sum of US$ 132.9 million and current liabilities were in the sum of US$ 98.3 million. About Ituran Ituran is a leader in the emerging mobility technology field, providing value-added location-based services, including a full suite of services for the connected-car. Ituran offers Stolen Vehicle Recovery, fleet management as well as mobile asset location, management & control services for vehicles, cargo and personal security for the retail, insurance industry and car manufacturers. Ituran is the largest OEM telematics provider in Latin America. Its products and applications are used by customers in over 20 countries. Ituran is also the founder of the Tel-Aviv based DRIVE startup incubator to promote the development of smart mobility technology. Ituran's subscriber base has been growing significantly since the Company's inception to over 2.5 million subscribers using its location-based services with a market leading position in Israel and Latin America. Established in 1995, Ituran has approximately 2,800 employees worldwide, with offices in Israel, Brazil, Argentina, Mexico, Ecuador, Columbia, India, Canada and the United States. For more information, please visit Ituran's website, at: Company Contact Udi Mizrahi udi_m@ Deputy CEO &VP Finance, Ituran (Israel) +972 3 557 1348 International Investor Relations Ehud Helft ituran@ EK Global Investor Relations (US) +1 212 378 8040 Logo - View original content: SOURCE Ituran Location and Control Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store